T
Thomas Powles
Researcher at Queen Mary University of London
Publications - 804
Citations - 57482
Thomas Powles is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 82, co-authored 655 publications receiving 39271 citations. Previous affiliations of Thomas Powles include Charing Cross Hospital & University of London.
Papers
More filters
Journal ArticleDOI
Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN+PEMBRO) or sunitinib (SUN) in the CLEAR study
Martin H. Voss,Thomas Powles,Bradley Alexander McGregor,Camillo Porta,Viktor Grünwald,J. Merchan,Frederic Rolland,Pablo Maroto-Rey,Jeffrey C. Goh,D Xing,Rodolfo F. Perini,J. McKenzie,Kalgi Mody,Robert J. Motzer +13 more
Journal ArticleDOI
Summary from the Kidney Cancer Association’s Inaugural Think Thank: Coalition for a Cure
Brian I. Rini,E. Jason Abel,Laurence Albiges,Axel Bex,James Brugarolas,Ronald M. Bukowski,Jonathan A. Coleman,Charles G. Drake,Robert A. Figlin,Andy Futreal,Hans J. Hammers,Thomas Powles,W. Kimryn Rathmell,Christopher J. Ricketts,Samra Turajlic,Christopher G. Wood,Bradley C. Leibovich +16 more
TL;DR: This commentary summarizes the discussion of screening, imaging, rarer RCC subtypes, combination drug therapy options, and patient response, along with a proposal of projects for collaboration in overcoming those needs and making a greater impact on care for patients with RCC moving forward.
Journal ArticleDOI
Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial.
Syed A. Hussain,Jason F. Lester,Richard J. Jackson,Matthew Gornall,Muneeb Ahmed Qureshi,Anthony Elliott,Simon J. Crabb,Robert Huddart,Naveen S. Vasudev,Alison Birtle,Jane Worlding,Nicholas D. James,Omi Parikh,M Vilarino-Varela,Roberto Alonzi,Mark Linch,Irbaz Bin Riaz,James W.F. Catto,Thomas Powles,Robert Jones +19 more
TL;DR: NEOBLADE as discussed by the authors was a parallel-arm, double-blind, randomised, placebo-controlled, phase 2 trial of neoadjuvant gemcitabine and cisplatin chemotherapy with nintedanib or placebo in locally advanced muscle-invasive bladder cancer.
Proceedings ArticleDOI
Abstract CT031: Updated efficacy and safety profile of durvalumab monotherapy in urothelial carcinoma
Peter H. O'Donnell,Christophe Massard,Bhumsuk Keam,Sang-We Kim,Terry Friedlander,Myung-Ju Ahn,Michael Ong,Michael S. Gordon,Marcus O. Butler,Scott J. Antonia,Gerardo Colon-Otero,Martin Gutierrez,Sumati Gupta,Alexander I. Spira,Alexandra Drakaki,Michele Maio,Feng Xiao,Natasha Angra,Shaad Essa Abdullah,Thomas Powles +19 more
TL;DR: With extended follow-up, durvalumab continues to show durable clinical activity in UC pts, especially in the PD-L1 ≥25% group with an acceptable toxicity profile, as well as with an ongoing, phase 1/2 open-label study.
Journal ArticleDOI
Immune Checkpoint Inhibitors for Urologic Cancer: The Tip of the Iceberg?
TL;DR: A feature of immune therapy, highlighted by sipuleucel-T, is the lack of treatment-related response or delayed progression-free survival, one of the difficulties with immune therapy drug development.